The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance
- PMID: 2697181
The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance
Abstract
The expression of the epidermal growth factor receptor (EGF-R) and the c-myc oncogene was investigated in different specimens of ovarian and cervical carcinomas. The EGF-Rs were analyzed by EGF binding assay, immunohistochemistry and Northern blotting. For analysis of c-myc expression, we used Northern blotting and immunohistochemistry. Furthermore, tissue concentrations of EGF-like factors (EGF-F) were measured in the same tumor and non-malignant specimens. The biochemical determination of EGF-R demonstrated that EGF specific binding sites were detected in 36% of ovarian (n = 140) and 81% of cervical carcinomas (n = 42). High amounts of EGF-R (greater than 10 fmol/mg specific binding) were found in 8% of the ovarian and 41% of the cervical carcinomas. Increased expression of EGF-R specific mRNA was detectable in 7/21 ovarian and in 5/7 cervical carcinomas. A positive correlation between the amounts of EGF-R mRNA, the EGF-R binding data and the staining index of EGF-R immunohistochemistry was found. The EGF-R immunohistochemistry demonstrates that only the tumor cells produce increased amounts of EGF-R, while the stromal cells are EGF-R negative. Low amounts of EGF-R specific mRNA were also detected in biochemically EGF-R negative tumors. The c-myc specific mRNA signal was found in all cases investigated. It is shown that the c-myc expression was increased in 10/21 ovarian and 5/7 cervical carcinomas. There was no positive correlation between the amounts of EGF-R and c-myc mRNAs. The product of myc, as detected by immunohistochemistry, is found in tumor as well as in stromal cells. The levels of EGF-F were measured in extracts of 63 ovarian and 12 cervical carcinomas and in 21 non-malignant tissues. About 30% of the tumor extracts contained higher EGF-F levels (4-15 ng/mg) than those found in the non-malignant specimens. Tumors with high EGF-F levels expressed high amounts of c-myc RNA. The EGF-R status (n = 111) and the EGF-F levels (n = 63) were related to the prognosis of survival for patients with ovarian carcinomas. EGF-R positive (EGF-R(+)) ovarian carcinomas had a significantly higher response rate to chemotherapy. The survival time of the EGF-R(+) group is reduced compared to the EGF-R negative (EGF-R(-)) group if only patients in remission are used to construct survival curves. Furthermore, a poor prognosis for survival was noticed for ovarian carcinoma patients with high EGF-F levels.
Similar articles
-
Expression analysis of EGF-R and TGFa in human ovarian carcinomas.Anticancer Res. 1991 Jul-Aug;11(4):1523-8. Anticancer Res. 1991. PMID: 1746909
-
Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.Anticancer Res. 1991 Jul-Aug;11(4):1485-94. Anticancer Res. 1991. PMID: 1660689
-
Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation.J Cell Biochem. 1989 Nov;41(3):139-57. doi: 10.1002/jcb.240410305. J Cell Biochem. 1989. PMID: 2482293
-
The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies.Dan Med Bull. 1998 Apr;45(2):121-34. Dan Med Bull. 1998. PMID: 9587699 Review.
-
The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).Anticancer Res. 1989 Sep-Oct;9(5):1265-79. Anticancer Res. 1989. PMID: 2686529 Review.
Cited by
-
Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.J Ovarian Res. 2017 Apr 26;10(1):31. doi: 10.1186/s13048-017-0319-2. J Ovarian Res. 2017. PMID: 28446239 Free PMC article.
-
Growth factors in ovarian cancer.Br J Cancer. 1991 Dec;64(6):1177-81. doi: 10.1038/bjc.1991.486. Br J Cancer. 1991. PMID: 1764384 Free PMC article.
-
The Notch pathway in ovarian carcinomas and adenomas.Br J Cancer. 2005 Sep 19;93(6):709-18. doi: 10.1038/sj.bjc.6602719. Br J Cancer. 2005. PMID: 16136053 Free PMC article.
-
Comparison of different scoring systems for immunohistochemical staining.J Clin Pathol. 1999 Jan;52(1):75-7. doi: 10.1136/jcp.52.1.75. J Clin Pathol. 1999. PMID: 10343618 Free PMC article.
-
Id-I stimulates cell proliferation through activation of EGFR in ovarian cancer cells.Br J Cancer. 2004 Dec 13;91(12):2042-7. doi: 10.1038/sj.bjc.6602254. Br J Cancer. 2004. Retraction in: Br J Cancer. 2021 May;124(10):1748. doi: 10.1038/s41416-021-01322-z. PMID: 15599381 Free PMC article. Retracted.